Lv1
30 积分 2023-11-13 加入
The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
2小时前
求助中
Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma
21天前
已完结
Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma
1个月前
已完结
Mutations of ARID1B, PIK3C2B, KMT2B, and FAT1 genes influence clinical outcome in newly diagnosed myeloma
1个月前
已完结
Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study
1个月前
已完结
Preoperative tumor abnormal protein is a promising biomarker for predicting hepatocellular carcinoma oncological outcome following curative resection
2个月前
已完结
Clinical application of serum tumor abnormal protein combined with tumor markers in lung cancer patients
2个月前
已完结
Advancements in Bispecific Antibodies for Multiple Myeloma: What's New and What Lies Ahead
4个月前
已完结
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial
4个月前
已关闭
Phase I Trial of MCARH109, a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis
4个月前
已完结
皖公网安备34019202002308
